Navigation Links
Roxane Laboratories, Inc. Announces the Launch of Granisetron Hydrochloride Tablets, 1mg
Date:1/3/2008

COLUMBUS, Ohio, Jan. 2 /PRNewswire/ -- Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA) for Granisetron Hydrochloride Tablets, 1mg by the U.S. Food and Drug Administration. The product is available in Unit Dose Blisters and is available for immediate shipment to wholesalers and pharmacies nationwide.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070410/CLTU122LOGO )

Roxane Laboratories' Granisetron Hydrochloride Tablets are AB rated to KYTRIL(R) (granisetron hydrochloride) Tablets. Annual sales of Granisetron Hydrochloride Tablets, 1mg are approximately $89 Million(1).

Full prescribing information for Granisetron Hydrochloride Tablets is available on the Roxane Laboratories website at http://www.Roxane.com or upon request by calling Roxane Laboratories Technical Product Information at 1.800.962.8364.

About Roxane Laboratories, Inc.

Roxane Laboratories is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people. Currently, Roxane Laboratories markets over 75 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled-release tablets; nasal sprays, cytotoxics and CII narcotics.

Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and approximately 38,400 employees
'/>"/>

SOURCE Roxane Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Roxane Laboratories, Inc. Announces the Launch of Balsalazide Disodium Capsules, 750mg
2. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
4. Bond Laboratories, Inc. Announces 2-for-1 Forward Split
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R)
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
7. Getting Ready Corporation and Winston Laboratories, Inc. Announce Merger Agreement
8. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
9. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Second Quarter Earnings
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2009)...BEND, Ind., Jan. 8 Press Ganey Ass...ientFlow Technology (PatientFlow), a,leading prov... for hospitals.,The Boston-based company speciali...strategic solutions for patient flow issues such a...umped or delayed surgeries, and lack of,available...
(Date:1/7/2009)...CH, Fla., Jan. 7 Non-profits Medical Tourism Asso...Monterrey Health Care City ( www.monterreyciudad...te the 1st Latin America Medical Tourism and Healt...09 in Monterrey, Mexico at the Intercontinental Pr...stinations of medical tourism in Latin America, ha...
(Date:1/7/2009)...., Jan. 7 Insulet Corporation (Nasdaq: PODD ), ...od(R) Insulin Management System, today announced t.... Morgan Healthcare Conference. Management is sche...0 a.m. PST on January 14, 2009 at The Westin St. F...rence presentation, material information concernin...
(Date:1/7/2009)..., Tenn., Jan. 7 Ambulatory Services of America,In...a, LLC, its seventh,radiation oncology joint ventu...g Gulf Coast Cancer Center - Gulf Shores, P.C., Mo...abama Radiation Oncology, P.C., and ASA,s,subsidia...ROSA of South,Alabama will own and operate four ra...
Breaking Medicine News(10 mins):Health News:Press Ganey Acquires PatientFlow Technology 2Health News:The Non-Profits Medical Tourism Association (MTA), Monterrey Health Care City (MHCC) Have Partnered Together to Create the 1st Latin America Medical Tourism and Health Tourism Congress Which Occurs April 27-29th, 2009 in Monterrey, Mexico at the Intercont 2Health News:The Non-Profits Medical Tourism Association (MTA), Monterrey Health Care City (MHCC) Have Partnered Together to Create the 1st Latin America Medical Tourism and Health Tourism Congress Which Occurs April 27-29th, 2009 in Monterrey, Mexico at the Intercont 3Health News:The Non-Profits Medical Tourism Association (MTA), Monterrey Health Care City (MHCC) Have Partnered Together to Create the 1st Latin America Medical Tourism and Health Tourism Congress Which Occurs April 27-29th, 2009 in Monterrey, Mexico at the Intercont 4Health News:Ambulatory Services of America, Inc. Announces Joint Venture with Gulf Coast Cancer Centers 2
...sts at the University of Canberra claim that they ...viour of children. // Positive parenting program w... master unit, with an intention to make parenting ... anxiety levels in parents by altering children’s ...
...tending the 16th International AIDS Conference in ...ica are at risk of plunging into a silent epidemic...Middle East and North Africa carry the virus that ...s the lowest rate of HIV infection in the world ac...
...nsplant at TG Hospital gave a B.C. youngster a bow...rince George, B.C. was told to prepare// for the d...o prepare and to accept, but I still wasn't on tha...recovering following a high-risk, four-organ trans...
...o improve the management of the Queensland's healt... has called for a doctor to head the system//. Dr ... that Dr Bruce Flegg, the new Liberal leader, coul...iling system and added that Peter Beattie Governme...
Other Medicine News:Health News:Parenting skills to manage bad behaviour 2Health News:Risk of Silent AIDS epidemic in Middle East and North Africa 2Health News:Rare Transplant Gives B.C Youngster 4 New Organs 2Health News:Rare Transplant Gives B.C Youngster 4 New Organs 3
(Date:1/7/2009)...RNewswire/ -- Circassia Ltd, a specialty,biopharm...care, today,announced that following successful c...une(R) anti-allergy technology, the company has no...se II clinical trial in cat allergy. The,study, w...ents with confirmed,cat allergies, and all the pa...
(Date:1/6/2009)...e-USNewswire/ -- Sequella, Inc., a clinical-stage ...pidemic potential, announced today that SQ109, its...osis (TB), was the first drug approved for evaluat...o Dynport Vaccine Company LLC and Quintiles Transn...titute of Allergy and Infectious Diseases (NIAID),...
(Date:1/5/2009)...wire-FirstCall/ -- Micromet, Inc.,(Nasdaq: MITI...proprietary,antibodies for the treatment of cance... an outlook on key events anticipated for the year...pdate on its research and development,programs at... 2009: Update on several preclinical BiTE antibodi...
(Date:12/27/2008)...Newswire-FirstCall/ -- Warner Chilcott Limited (Na...sidiaries and Mayne Pharma International Pty. Ltd....led lawsuits against each of Mutual Pharmaceutical...nc. ("Mylan") and Impax Laboratories, Inc. ("Impax...Jersey for infringement of Mayne,s U.S. Patent No....
Breaking Medicine Technology:Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 3Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Micromet Key Events for 2009 2Micromet Key Events for 2009 3Micromet Key Events for 2009 4Micromet Key Events for 2009 5Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 2Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 3UNIFEM and Avon Announce Partnership to End Violence Against Women and Advance Womens Empowerment 3A Company Contribution Benefits UN Trust Fund 13478 1UNIFEM and Avon Announce Partnership to End Violence Against Women and Advance Womens Empowerment 3A Company Contribution Benefits UN Trust Fund 13478 2UNIFEM and Avon Announce Partnership to End Violence Against Women and Advance Womens Empowerment 3A Company Contribution Benefits UN Trust Fund 13478 3UNIFEM and Avon Announce Partnership to End Violence Against Women and Advance Womens Empowerment 3A Company Contribution Benefits UN Trust Fund 13478 4UNIFEM and Avon Announce Partnership to End Violence Against Women and Advance Womens Empowerment 3A Company Contribution Benefits UN Trust Fund 13478 5LA BioMed researcher says unexpected increase in cancer risk found 13475 1LA BioMed researcher says unexpected increase in cancer risk found 13475 2LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 1LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 2LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 3LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 4LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 5LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 6LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 7LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 8LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 9LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 10LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 11LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 12Bristol Myers Squibb Announces Dividend 3710 1
...erland, April 25, 2007 - Basilea Pharmaceutica Ltd...s showing that,patients with severe chronic hand e...oin. In two previous randomized clinical,trials, a...severe,chronic hand eczema in patients refractory ...ated that patients responsive to initial,treatment...
....--(BUSINESS WIRE)--Apr 25, 2007 - OSI,Pharmaceuti...ults,published yesterday in the Journal of Clinica... to gemcitabine chemotherapy,significantly improve... to patients with advanced pancreatic cancer. Data... Institute of Canada (NCIC),formed the basis of b...
Other Medicine Technology:Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 2Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 3Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 4Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 5OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 2OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 3OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 4
STABIBAG Hydrophilic Acrylic Lens.
XL STABI Hydrophilic Acrylic Lens.
FZ60 : the 1st monobloc hard & soft IOL. Thanks to an exclusive and patented process : the selective polymerisation, IOLTECH designed the first single piece rigid & soft IOL : the FZ60. This technolo
XL OCTO Hydrophilic Acrylic Lens.
Medicine Products: